Please note that following on from information provided to NICE by the company in July 2020, the appraisal of Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 1606

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
20 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in July 2020, the appraisal of Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

For further information on how we select topics for development, please see our page about topic selection